Top

Published in:

01-06-2014 | Clinical Study

Decreased expression of LASS2 is associated with worse prognosis in meningiomas

Authors: Rong-Hu Ke, Yin Wang, Yin Mao, Jun Zhang, Ji Xiong

Published in: Journal of Neuro-Oncology | Issue 2/2014

Abstract

Homo sapiens longevity assurance homolog 2 of yeast LAG1 (LASS2) has been indicated to have a critical role in various tumors. In the study, we aimed to evaluate the LASS2 expression level in prognostic significance and compare it with commonly used biomarkers: Ki-67, p53 and progesterone receptor (PR) for patients with meningiomas. Firstly, 50 fresh tissues and 143 paraffin-embedded meningiomas samples were analyzed for LASS2 expression by quantitative PCR and immunohistochemistry (IHC), respectively. Subsequently, LASS2 immunostaining was evaluated for its clinical significance. Furthermore, Correlations of LASS2 expression with common biomarkers were assessed. Both PCR and IHC results showed LASS2 was downregulated in high-grade meningiomas in comparison with that of grade I or normal brain (all P < 0.01). IHC results demonstrated LASS2 intensity distribution (ID) score was significantly correlated with tumor size, brain invasion, tumor recurrence and clinical course (all P < 0.01), whereas no correlation of LASS2 ID score with sex or Simpson grade. Moreover, lower LASS2 ID score was strikingly associated with shorter overall and progression-free survival (P < 0.01). Pearson’s analysis revealed the ID score was significantly reversely associated with Ki-67 and p53 but not with PR. More importantly,multivariate analyses revealed that LASS2 was an independent prognostic factor (P < 0.05). To our knowledge, it is the first time to investigate the expression of LASS2 and identify it as a potential biomarker for prognosis in meningiomas.

Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275–286PubMed

Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045–1054PubMedCrossRef

Adegbite AB, Khan MI, Paine KW, Tan LK (1983) The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58:51–56PubMedCrossRef

Espinosa A, Tabernero MD, Maillo A et al (2006) The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res 12:772–780PubMedCrossRef

Pan H, Qin WX, Huo KK et al (2001) Cloning, mapping, and characterization of a human homologue of the yeast longevity assurance gene LAG1. Genomics 77:58–64PubMedCrossRef

Laviad EL, Albee L, Pankova-Kholmyansky I et al (2008) Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283:5677–5684PubMedCrossRef

Imgrund S, Hartmann D, Farwanah H et al (2009) Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J Biol Chem 284:33549–33560PubMedCentralPubMedCrossRef

Xu X, You J, Pei F (2012) Silencing of a novel tumor metastasis suppressor gene LASS2/TMSG1 promotes invasion of prostate cancer cell in vitro through increase of vacuolar ATPase activity. J Cell Biochem 113:2356–2363PubMedCrossRef

Schiffmann S, Sandner J, Birod K et al (2009) Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 30:745–752PubMedCrossRef

10.

Mesicek J, Lee H, Feldman T et al (2010) Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal 22:1300–1307PubMedCrossRef

11.

Wang H, Wang J, Zuo Y et al (2011) Expression and prognostic significance of a new tumor metastasis suppressor gene LASS2 in human bladder carcinoma. Med Oncol 29:1921–1927PubMedCrossRef

12.

Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In: Louis DN, Oghaki H, Wiesttler D, Cavenee WK (eds) WHO classification of tumors of the central nervous system, 4th edn. IARC Press, Lyon, pp 164–172

13.

Ke HL, Ke RH, Li ST et al (2013) Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression. J Neurooncol 113:327–332PubMedCrossRef

14.

Barresi V, Cerasoli S, Paioli G et al (2006) Caveolin-1 in meningiomas: expression and clinicopathological correlations. Acta Neuropathol 112:617–626PubMedCrossRef

15.

Fan S, Niu Y, Tan N et al (2013) LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. Oncogene 32:1682–1690PubMedCrossRef

16.

Nishi T, Forgac M (2002) The vacuolar H⁺-ATPases—nature’s most versatile proton pumps. Nat Rev Mol Cell Biol 3:94–103PubMedCrossRef

17.

Otero-Rey EM, Somoza-Martín M, Barros-Angueira F, García-García A (2008) Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene. Oral Oncol 44:193–199PubMedCrossRef

18.

Petzoldt AG, Gleixner EM, Fumagalli A, Vaccari T, Simons M (2013) Elevated expression of the V-ATPase C subunit triggers JNK-dependent cell invasion and overgrowth in a Drosophila epithelium. Dis Model Mech 6:689–700PubMedCentralPubMedCrossRef

19.

Lu X, Qin W, Li J et al (2005) The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 65:6843–6849PubMedCrossRef

20.

Yu W, Wang L, Wang Y et al (2013) A novel tumor metastasis suppressor gene LASS2/TMSG1 interacts with vacuolar ATPase through its homeodomain. J Cell Biochem 114:570–583PubMedCrossRef

Title: Decreased expression of LASS2 is associated with worse prognosis in meningiomas
Authors: Rong-Hu Ke
Yin Wang
Yin Mao
Jun Zhang
Ji Xiong
Publication date: 01-06-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1441-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Decreased expression of LASS2 is associated with worse prognosis in meningiomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Intracranial ganglioglioma WHO I: results in a series of eight patients treated with stereotactic interstitial brachytherapy

Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis

Exogenous endothelin-1 induces cell migration and matrix metalloproteinase expression in U251 human glioblastoma multiforme

Weight of epilepsy in brain tumor patients

Whole brain reirradiation and concurrent temozolomide in patients with brain metastases

ROS1 translocations and amplifications in lung cancer brain metastases